Spots Global Cancer Trial Database for objective response rate
Every month we try and update this database with for objective response rate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Real-world Study for Patients With Advanced Hepatobiliary Tumors | NCT03892577 | Objective Respo... Progression-fre... Overall Surviva... Disease Control... Duration of Res... Five-year Survi... Quality of Life | Precision oncol... | 18 Years - | Peking Union Medical College Hospital | |
| Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma | NCT01466868 | Diffuse Large B... | MK2206 | 18 Years - 90 Years | Centre Leon Berard | |
| Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors | NCT05760196 | Objective Respo... | GM-CSF | 18 Years - | Renmin Hospital of Wuhan University | |
| A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments | NCT05152472 | Unresectable Ga... Locally Advance... Metastatic Gast... | Atezolizumab 12... Imatinib 400 MG | 18 Years - | Centre Leon Berard | |
| Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer | NCT02124317 | Advanced Pancre... | nanoparticle al... S-1 | 18 Years - | Chinese PLA General Hospital | |
| Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer | NCT04670978 | Objective Respo... | albumin-bound p... | 18 Years - 70 Years | Shandong University | |
| Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy | NCT06125834 | Advanced Breast... Objective Respo... Trastuzumab Emt... | Trastuzumab Emt... | 18 Years - 70 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer | NCT05503108 | Fasting Mimicki... HER2-negative B... Hormone Recepto... Pathological Co... Objective Respo... Neoadjuvant Che... | Fasting Mimicki... | 18 Years - | Leiden University Medical Center | |
| Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients | NCT04698785 | Bone Sarcoma Osteosarcoma | Treatment by re... Treatment by pl... | 12 Years - | Centre Leon Berard | |
| Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) | NCT01323400 | GIST | Pazopanib Best supportive... | 18 Years - 90 Years | Centre Leon Berard | |
| Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma | NCT02366195 | Unresected Stag... | Talimogene Lahe... | 18 Years - | Amgen | |
| Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | NCT04156698 | Hypopharyngeal ... Immunotherapy Chemotherapy | Docetaxel Cisplatin Capecitabine Camrelizumab | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients | NCT04698785 | Bone Sarcoma Osteosarcoma | Treatment by re... Treatment by pl... | 12 Years - | Centre Leon Berard | |
| Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients | NCT01192230 | Carcinoma, Non-... | Endostatins Docetaxel | 18 Years - 80 Years | Fudan University | |
| H101 Combined With Camrelizumab for Recurrent Cervical Cancer | NCT05234905 | Uterine Cervica... Oncolytic Virot... Camrelizumab | Recombinant hum... | 18 Years - 80 Years | Zhejiang Cancer Hospital | |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma | NCT04664244 | Recurrent Cervi... Radiotherapy Epidermal Growt... Nimotuzumab Objective Respo... Progression-fre... Overall Surviva... | Combination of ... | 18 Years - | Peking Union Medical College Hospital | |
| Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | NCT04156698 | Hypopharyngeal ... Immunotherapy Chemotherapy | Docetaxel Cisplatin Capecitabine Camrelizumab | 18 Years - 70 Years | Eye & ENT Hospital of Fudan University | |
| Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype | NCT04741438 | Sarcoma | Nivolumab and I... Pazopanib Oral ... | 18 Years - | Centre Leon Berard | |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer | NCT05310383 | Recurrent Cervi... Metastatic Cerv... Persistent Cerv... Radiotherapy Immunotherapy Anti-programmed... Immune Checkpoi... Tislelizumab Objective Respo... Survival Outcom... | Tislelizumab pl... | 18 Years - | Peking Union Medical College Hospital | |
| Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients | NCT01192243 | Toxicity Non-small Cell ... | Gefitinib Pemetrexed Cisplatin or ca... | 18 Years - 70 Years | Fudan University | |
| Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer | NCT04102982 | NSCLC Stage IV | Camrelizumab Camrelizumab pl... | 18 Years - 80 Years | Shandong Provincial Hospital | |
| Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients | NCT01192243 | Toxicity Non-small Cell ... | Gefitinib Pemetrexed Cisplatin or ca... | 18 Years - 70 Years | Fudan University | |
| Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer | NCT05503108 | Fasting Mimicki... HER2-negative B... Hormone Recepto... Pathological Co... Objective Respo... Neoadjuvant Che... | Fasting Mimicki... | 18 Years - | Leiden University Medical Center | |
| Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer | NCT06276868 | Breast Cancer HER2-positive B... | Dalcilib+letroz... | 18 Years - 70 Years | Henan Cancer Hospital | |
| Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype | NCT04741438 | Sarcoma | Nivolumab and I... Pazopanib Oral ... | 18 Years - | Centre Leon Berard | |
| Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE) | NCT02014831 | Squamous Cell C... | Cetuximab TIP | 18 Years - | Centre Leon Berard | |
| Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas | NCT04635956 | Chemotherapy Anti-pd-1 Antib... Cervical Neuroe... Adverse Drug Ev... Recurrent Cervi... Advanced Cervic... Objective Respo... | Drug therapy | 18 Years - | Peking Union Medical College Hospital | |
| Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype | NCT04741438 | Sarcoma | Nivolumab and I... Pazopanib Oral ... | 18 Years - | Centre Leon Berard | |
| R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse | NCT05257018 | Diffuse Large B... | R-CDOP+intrathe... | 18 Years - 75 Years | Fudan University | |
| Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors | NCT05760196 | Objective Respo... | GM-CSF | 18 Years - | Renmin Hospital of Wuhan University | |
| Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma | NCT02366195 | Unresected Stag... | Talimogene Lahe... | 18 Years - | Amgen | |
| High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor | NCT05755009 | Metastatic Canc... | High- and Low-d... | 18 Years - 70 Years | Jiangxi Provincial Cancer Hospital | |
| Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma | NCT04664244 | Recurrent Cervi... Radiotherapy Epidermal Growt... Nimotuzumab Objective Respo... Progression-fre... Overall Surviva... | Combination of ... | 18 Years - | Peking Union Medical College Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
